WO2023150307A3 - Compositions and methods against a virus - Google Patents

Compositions and methods against a virus Download PDF

Info

Publication number
WO2023150307A3
WO2023150307A3 PCT/US2023/012337 US2023012337W WO2023150307A3 WO 2023150307 A3 WO2023150307 A3 WO 2023150307A3 US 2023012337 W US2023012337 W US 2023012337W WO 2023150307 A3 WO2023150307 A3 WO 2023150307A3
Authority
WO
WIPO (PCT)
Prior art keywords
variants
cov
sars
hca
antibody
Prior art date
Application number
PCT/US2023/012337
Other languages
French (fr)
Other versions
WO2023150307A2 (en
Inventor
Shaun MURPHY
Adam PELZEK
Sanam EBTEHAJ
James LULO
Gang An
Lin CAO
Bai Lu
Yang DOU
Jianfeng Pan
Lingjie Xu
Xiaoyu Xu
Original Assignee
Abpro Corporation
Vazyme Biotech Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abpro Corporation, Vazyme Biotech Co., Ltd filed Critical Abpro Corporation
Publication of WO2023150307A2 publication Critical patent/WO2023150307A2/en
Publication of WO2023150307A3 publication Critical patent/WO2023150307A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

COVID-19 is the deadliest respiratory virus pandemic since 1918 and the latest of several coronavirus epidemics and pandemics in recent years. Despite the unprecedented response by both the government and private sectors to develop vaccines and therapies, the evolution of SARS-CoV-2 variants resistant to these interventions reveals a crucial need for therapeutics that maintain their efficacy against current and future mutant variants. The disclosure herein provides a SARS-CoV-2 neutralizing antibody, the HCA/LCA antibody, with potent activity against all variants tested including the Omicron variant. The HCA/LCA antibody also displays potent neutralizing activity against SARS-CoV. The presently disclosed HCA/LCA antibody can provide a therapeutic effect against the current SARS-CoV-2 variants and can maintain efficacy against future variants and novel coronaviruses.
PCT/US2023/012337 2022-02-03 2023-02-03 Compositions and methods against a virus WO2023150307A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202263306276P 2022-02-03 2022-02-03
US63/306,276 2022-02-03
US202263316262P 2022-03-03 2022-03-03
US63/316,262 2022-03-03
CN2022081104 2022-03-16
CNPCT/CN2022/081104 2022-03-16

Publications (2)

Publication Number Publication Date
WO2023150307A2 WO2023150307A2 (en) 2023-08-10
WO2023150307A3 true WO2023150307A3 (en) 2023-11-30

Family

ID=87552857

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/012337 WO2023150307A2 (en) 2022-02-03 2023-02-03 Compositions and methods against a virus

Country Status (1)

Country Link
WO (1) WO2023150307A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021233927A1 (en) * 2020-05-18 2021-11-25 Ignova Gmbh Antibody that binds specifically to the sars cov 2 spike protein, and methods for its manufacture
US20210371504A1 (en) * 2020-02-26 2021-12-02 Vir Biotechnology, Inc. Antibodies against sars-cov-2 and methods of using the same
US20210371503A1 (en) * 2020-05-29 2021-12-02 University Of Cologne Neutralizing antibodies against sars-related coronavirus

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210371504A1 (en) * 2020-02-26 2021-12-02 Vir Biotechnology, Inc. Antibodies against sars-cov-2 and methods of using the same
WO2021233927A1 (en) * 2020-05-18 2021-11-25 Ignova Gmbh Antibody that binds specifically to the sars cov 2 spike protein, and methods for its manufacture
US20210371503A1 (en) * 2020-05-29 2021-12-02 University Of Cologne Neutralizing antibodies against sars-related coronavirus

Also Published As

Publication number Publication date
WO2023150307A2 (en) 2023-08-10

Similar Documents

Publication Publication Date Title
Abdullahi Safety and efficacy of chest physiotherapy in patients with COVID-19: a critical review
Trivedi et al. Possible treatment and strategies for COVID-19: review and assessment.
CO2022015415A2 (en) Antiviral application of nucleoside analogue or combination formulation containing nucleoside analogue
WO2021207409A3 (en) Small molecule inhibitors of sars-cov-2 viral replication and uses thereof
BR112022026899A2 (en) COMPOUND REPRESENTED BY FORMULA (I) OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PHARMACEUTICAL COMPOSITION, METHOD OF TREATMENT OR PREVENTION OF A VIRAL INFECTION, METHOD OF INHIBITING VIRAL PROTEASE 3C OR VIRAL PROTEASE 3CL IN A MAMMAL, AND METHOD OF TREATMENT OF A DISORDER RESPIRATORY
BR112018011803A2 (en) method and mechanism for gas administration including nitric oxide
PE20160195A1 (en) USE OF PRIDOPIDINE IN HIGH DOSES FOR THE TREATMENT OF HUNTINGTON DISEASE
JP2015534562A5 (en)
PH12020551709A1 (en) Antiviral immunotropic agent for the treatment of acute respiratory viral infections
Alkotaji Azithromycin and ambroxol as potential pharmacotherapy for SARS-CoV-2
BR112014018953A8 (en) TRITERPENOID LUPANE DERIVATIVES AND PHARMACEUTICAL USE THEREOF
BR112012032358A2 (en) process for the preparation of dronedarone
MX2021010834A (en) Compound and method for the prevention of transmission of influenza virus.
BR112013018598A2 (en) pharmaceutical composition, method for treating heart disease, use of (s) -methyl-3- [4- (2-hydroxy-3- [4- (2-hydroxy-3-isopropylamino) propoxy] phenylpropionate, and method for control heart rate
BR112014004435A2 (en) rock kinase inhibitors
MX2022015554A (en) Small molecule modulators of il-17.
WO2023150307A3 (en) Compositions and methods against a virus
Yang et al. Use of hydroxychloroquine and interferon alpha-2b for the prophylaxis of COVID-19
US20090318379A1 (en) Statins for the Treatment of Viral Influenza Infections
MX2022011885A (en) Pharmaceutical composition for preventing or treating epidemic rna viral infectious disease.
BR112023000308A2 (en) USE OF TAUROLIDINE AGAINST VIRUSES
WO2021156404A3 (en) Treatment of hpv-related diseases
CL2021003312A1 (en) Composition comprising pridopidine and an analog thereof for the treatment of huntington's disease and its symptoms.
WO2022023533A3 (en) Antiviral use of liraglutide and gefitinib
BR112018072177A2 (en) pharmaceutical composition, container, and methods for treating and preventing nasal congestion, viral respiratory tract infections and / or throat inflammation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23750230

Country of ref document: EP

Kind code of ref document: A2